329 related articles for article (PubMed ID: 17643778)
1. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
[TBL] [Abstract][Full Text] [Related]
2. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
3. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
4. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
5. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
6. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
Weinreb NJ; Charrow J; Andersson HC; Kaplan P; Kolodny EH; Mistry P; Pastores G; Rosenbloom BE; Scott CR; Wappner RS; Zimran A
Am J Med; 2002 Aug; 113(2):112-9. PubMed ID: 12133749
[TBL] [Abstract][Full Text] [Related]
8. Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy.
Zevin S; Abrahamov A; Hadas-Halpern I; Kannai R; Levy-Lahad E; Horowitz M; Zimran A
Q J Med; 1993 Sep; 86(9):565-73. PubMed ID: 8255971
[TBL] [Abstract][Full Text] [Related]
9. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.
Kaplan P; Andersson HC; Kacena KA; Yee JD
Arch Pediatr Adolesc Med; 2006 Jun; 160(6):603-8. PubMed ID: 16754822
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
[TBL] [Abstract][Full Text] [Related]
11. [French results of enzyme replacement therapy in Gaucher's disease].
Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
[TBL] [Abstract][Full Text] [Related]
12. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
13. Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy.
Burrow TA; Cohen MB; Bokulic R; Deutsch G; Choudhary A; Falcone RA; Grabowski GA
J Pediatr; 2007 Feb; 150(2):202-6. PubMed ID: 17236903
[TBL] [Abstract][Full Text] [Related]
14. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.
Boomsma JM; van Dussen L; Wiersma MG; Groener JE; Aerts JM; Maas M; Hollak CE
Blood Cells Mol Dis; 2010 Mar; 44(3):181-7. PubMed ID: 20074983
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.
Schiffmann R; Heyes MP; Aerts JM; Dambrosia JM; Patterson MC; DeGraba T; Parker CC; Zirzow GC; Oliver K; Tedeschi G; Brady RO; Barton NW
Ann Neurol; 1997 Oct; 42(4):613-21. PubMed ID: 9382473
[TBL] [Abstract][Full Text] [Related]
17. Bone complications in children with Gaucher disease.
Bembi B; Ciana G; Mengel E; Terk MR; Martini C; Wenstrup RJ
Br J Radiol; 2002; 75 Suppl 1():A37-44. PubMed ID: 12036831
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy in type I Gaucher disease.
Kay AC; Saven A; Garver P; Thurston DW; Rosenbloom BF; Beutler E
Trans Assoc Am Physicians; 1991; 104():258-64. PubMed ID: 1845151
[No Abstract] [Full Text] [Related]
19. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
[TBL] [Abstract][Full Text] [Related]
20. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
Giraldo P; Latre P; Alfonso P; Acedo A; Alonso D; Barez A; Corrales A; Franco R; Roldan V; Serrano S; Pocovi M
Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
